Pulmatrix (PULM)

• Market cap: $21M
• 1 day: -4.00%
• 5 days: -8.86%
• 1 month: -4.64%
• 3 months: 165.44%
• 6 months: 198.45%
• Year to date: 195.38%
• 1 year: 195.38%
• 5 years: -66.12%
• 10 years: -99.19%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.

Employees: 22

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

17% more capital invested

Capital invested by funds: $486K [Q2] → $566K (+$80.6K) [Q3]

8% more funds holding

Funds holding: 12 [Q2] → 13 (+1) [Q3]

0.36% more ownership

Funds ownership: 6.89% [Q2] → 7.25% (+0.36%) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3